molecules of the month


oral ATX inhibitor

negative outcomes in Ph. III in IPF
(200-600 mg QD)

from HTS and optimization

JAMA, May 9, 2023

Galapagos SASU, Romainville, FR

ziritaxestat, ATX, oral ATX inhibitor negative outcomes in Ph. III in IPF (200-600 mg QD), from HTS and optimization JAMA, May 9, 2023, GALAPAGOS SASU, ROMAINVILLE, FR
9 mins read

(GLPG1690): The First Clinical Autotaxin (ATX) Inhibitor for IPF Ziretaxestat, an oral autotaxin (ATX) inhibitor originated by Galapagos, once garnered excitement as the first molecule to complete a Ph. III clinical program in idiopathic pulmonary fibrosis since the approvals of nintedanib and pirfenidone. Following the disappointing clinical data and discontinuation of the molecule, this annotation revisits ziritaxestat in the context of other inhibitors, recaps the therapeutic hypothesis and how it was discovered, summarizes notable molecular properties for drug discovery scientists, and discusses what happened and what’s next. Reviewer Christian Kuttruff comments, “I think what is important to the Ziritaxestat story is that it was the first phase 3 clinical trial program in IPF to be completed since the approval of…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: